Literature DB >> 18838414

Retinoblastoma: treatment and survival in Great Britain 1963 to 2002.

A MacCarthy1, J M Birch, G J Draper, J L Hungerford, J E Kingston, M E Kroll, C A Stiller, T J Vincent, M F G Murphy.   

Abstract

AIM: This paper describes the treatment and survival of 1576 children with retinoblastoma in Great Britain diagnosed 1963-2002.
METHODS: Survival rates were analysed according to period of diagnosis and tumour laterality.
RESULTS: Survival was calculated by calendar period of diagnosis, 1963-1982 and 1983-2002. For both unilateral and bilateral retinoblastoma, survival improved between the two periods. The survival curves for the two periods were significantly different: for unilateral retinoblastoma p<0.00001, for bilateral p<0.01. For unilateral cases, the estimated 5-year survival rates rose from 85% for those diagnosed in 1963-1967 to 97% for those diagnosed in 1998-2002. The equivalent rates for bilateral cases were 88% and 100%.
CONCLUSION: Survival rates were already high at the start of the study period. They increased with changes in treatment regimens.

Entities:  

Mesh:

Year:  2008        PMID: 18838414     DOI: 10.1136/bjo.2008.139626

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  22 in total

1.  The National Registry of Retinoblastoma in Japan (1983-2014).

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2018-05-30       Impact factor: 2.447

2.  [Value of serum miR-17-92 cluster in diagnosis of retinoblastoma].

Authors:  Yan-Zhao Chen; Zhi-Ping Liu; Ke-Ying Zhou; Bo Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

Review 3.  The management of retinoblastoma.

Authors:  Ido D Fabian; Zerrin Onadim; Esin Karaa; Catriona Duncan; Tanzina Chowdhury; Irene Scheimberg; Shin-Ichi Ohnuma; M Ashwin Reddy; Mandeep S Sagoo
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

4.  Anterior chamber enhancement predicts optic nerve infiltration in retinoblastoma.

Authors:  Katerina Deike-Hofmann; Paula von Lampe; Maija Eerikaeinen; Saskia Ting; Sabrina Schlüter; Heinz-Peter Schlemmer; Nikolaos E Bechrakis; Michael Forsting; Alexander Radbruch
Journal:  Eur Radiol       Date:  2022-05-07       Impact factor: 5.315

5.  Liposome-based multifunctional nanoplatform as effective therapeutics for the treatment of retinoblastoma.

Authors:  Ying Liu; Yu Han; Shizhu Chen; Jingjie Liu; Dajiang Wang; Yifei Huang
Journal:  Acta Pharm Sin B       Date:  2021-10-22       Impact factor: 14.903

6.  Second primary tumors in retinoblastoma survivors: a study of 7 Asian Indian patients.

Authors:  Swathi Kaliki; Vijay Anand Reddy Palkonda
Journal:  Int Ophthalmol       Date:  2020-07-31       Impact factor: 2.031

7.  Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017.

Authors:  Jonathan E Lu; Jasmine H Francis; Ira J Dunkel; Carol L Shields; Michael D Yu; Jesse L Berry; Kaitlin Kogachi; Alison H Skalet; Audra K Miller; Pranav R Santapuram; Anthony B Daniels; David H Abramson
Journal:  Br J Ophthalmol       Date:  2018-10-25       Impact factor: 4.638

8.  Retinoblastoma in the democratic republic of congo: 20-year review from a tertiary hospital in kinshasa.

Authors:  Aimé Kazadi Lukusa; Michel Ntetani Aloni; Bertin Kadima-Tshimanga; Moïse Mvitu-Muaka; Jean Lambert Gini Ehungu; René Ngiyulu; Pépé Ekulu Mfutu; Aléine Budiongo Nzazi
Journal:  J Cancer Epidemiol       Date:  2012-04-26

Review 9.  Retinoblastoma in Asia.

Authors:  Mukesh Jain; Duangnate Rojanaporn; Bhavna Chawla; Gangadhar Sundar; Lingam Gopal; Vikas Khetan
Journal:  Eye (Lond)       Date:  2018-11-01       Impact factor: 3.775

10.  Eye Salvage with Intra-Arterial and Intra-Vitreal Chemotherapy in Patients with Retinoblastoma: 8-Year Single-Institution Experience in Colombia.

Authors:  María Elena González; Martha Lia Gaviria; Mariana López; Pablo Andrés Escudero; Andrés Bravo; Sergio Alberto Vargas
Journal:  Ocul Oncol Pathol       Date:  2021-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.